Literature DB >> 25873108

Effective targeting of primitive AML CD34+ cells by the second-generation proteasome inhibitor carfilzomib.

Lieke H van der Helm1, Matthieu C J Bosman1, Jan J Schuringa1, Edo Vellenga2.   

Abstract

Entities:  

Keywords:  acute leukaemia; bortezomib; carfilzomib; oprozomib; stem cells

Mesh：

Substances：

Year:  2015        PMID： 25873108     DOI： 10.1111/bjh.13418

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  7 in total

Review 1.  [Pemphigus. Model disease for targeted therapy].

Authors:  R Eming
Journal:  Hautarzt       Date:  2015-08       Impact factor: 0.751

Review 2.  Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.

Authors:  Robert Pollmann; Thomas Schmidt; Rüdiger Eming; Michael Hertl
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

Review 3.  Leukemic stem cells: identification and clinical application.

Authors:  Diana Hanekamp; Jacqueline Cloos; Gerrit Jan Schuurhuis
Journal:  Int J Hematol       Date:  2017-03-29       Impact factor: 2.490

4.  A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia.

Authors:  Lukas D Wartman; Mark A Fiala; Theresa Fletcher; Emily R Hawkins; Amanda Cashen; John F DiPersio; Meagan A Jacoby; Keith E Stockerl-Goldstein; Iskra Pusic; Geoffrey L Uy; Peter Westervelt; Ravi Vij
Journal:  Leuk Lymphoma       Date:  2015-10-05

Review 5.  The role of the proteasome in AML.

Authors:  C M Csizmar; D-H Kim; Z Sachs
Journal:  Blood Cancer J       Date:  2016-12-02       Impact factor: 11.037

6.  Inhibition of IRE1α RNase activity sensitizes patient-derived acute myeloid leukaemia cells to proteasome inhibitors.

Authors:  Stuart Creedican; Claire M Robinson; Katarzyna Mnich; Md Nahidul Islam; Eva Szegezdi; Ruth Clifford; Janusz Krawczyk; John B Patterson; Stephen P FitzGerald; Mark Summers; Ciaran Richardson; Kenneth Martin; Adrienne M Gorman; Afshin Samali
Journal:  J Cell Mol Med       Date:  2022-07-13       Impact factor: 5.295

7.  Hif-1α and Hif-2α synergize to suppress AML development but are dispensable for disease maintenance.

Authors:  Milica Vukovic; Amelie V Guitart; Catarina Sepulveda; Arnaud Villacreces; Eoghan O'Duibhir; Theano I Panagopoulou; Alasdair Ivens; Juan Menendez-Gonzalez; Juan Manuel Iglesias; Lewis Allen; Fokion Glykofrydis; Chithra Subramani; Alejandro Armesilla-Diaz; Annemarie E M Post; Katrin Schaak; Deniz Gezer; Chi Wai Eric So; Tessa L Holyoake; Andrew Wood; Dónal O'Carroll; Peter J Ratcliffe; Kamil R Kranc
Journal:  J Exp Med       Date:  2015-12-07       Impact factor: 14.307
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.